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Objective: Insomnia and depression are prevalent disorders that often co-occur. This
study aimed to investigate the impact of clinically significant insomnia symptoms on the
prevalence and clinical presentation of clinically significant depressive symptoms and
vice versa.
Methods: This study used data from the Korean Headache-Sleep Study (KHSS),
a nationwide cross-sectional population-based survey regarding headache and sleep.
Clinically significant insomnia symptoms were defined as Insomnia Severity Index
(ISI) scores ≥ 10 and clinically significant depressive symptoms were defined as
Patient Health Questionnaire-9 (PHQ-9) scores ≥ 10, respectively. We referred clinically
significant insomnia symptoms and clinically significant depressive symptoms as
insomnia symptoms and depressive symptoms, respectively.
Results: Of 2,695 participants, 290 (10.8%) and 116 (4.3%) were classified as
having insomnia and depressive symptoms, respectively. The prevalence of depressive
symptoms was higher among participants with insomnia symptoms than in those without
insomnia symptoms (25.9 vs. 1.7%, respectively, P < 0.001). Among participants
with depressive symptoms, the PHQ-9 scores were not significantly different between
participants with and without insomnia symptoms (P = 0.124). The prevalence
of insomnia symptoms was significantly higher among participants with depressive
symptoms than in those without depressive symptoms (64.7 vs. 8.3%, respectively, P
< 0.001). The ISI scores were significantly higher among participants with insomnia and
depressive symptoms than in participants with insomnia symptoms alone (P < 0.001).
Conclusions: Participants with depressive symptoms had a higher risk of insomnia
symptoms than did those without depressive symptoms. The severity of depressive
symptoms did not significantly differ based on insomnia symptoms among participants
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with depressive symptoms; however, the severity of insomnia symptoms was
significantly higher in participants with depressive symptoms than in those without
depressive symptoms.
Keywords: insomnia, depression, clinical presentation, prevalence, epidemiology
INTRODUCTION
Depression is a common mental health disorder that affects
approximately 4.4% of the global population (1). Owing to
its disabling symptoms and comorbidities, individuals with
depression experience an increased risk of functional impairment
and decreased quality of life (2). According to the Global Burden
of Diseases Study 2015, depression was ranked as the third
leading cause of disability among 310 disorders and injuries (3).
Insomnia is also a prevalent disorder that affects 9–15% of the
general population (4). Insomnia has significant negative effects
on various aspects of human functioning and is associated with
greater disability at work, school, and home (5). Furthermore,
individuals with insomnia reportedly use more health care
services (6).
In addition to being common disorders that induce significant
disability, depression, and insomnia are significantly associated
with each other. Individuals with depression often report
insomnia, which is an important symptom of depression.
Furthermore, insomnia was included as a symptom in the
diagnostic criteria of major depressive disorder (MDD) in the
Diagnostic and Statistical Manual of Mental Disorders (DSM)-
5 (7). Depression is reportedly more prevalent among those
with insomnia than among individuals without insomnia (8).
Longitudinal studies have shown that individuals with insomnia
have a higher risk of developing depression, while individuals
with depression have a higher risk of developing insomnia (9,
10). The existence of a bidirectional comorbidity suggests a
shared pathophysiological mechanism between depression and
insomnia (11).
Although a significant association between the two disorders
has been persistently reported based on their elevated prevalence
or co-occurrence, the literature features few clinic-based studies
of the impact of insomnia on the clinical presentation of
depression or vice versa. A clinic-based study including 4,041
patients with MDD reported that 84.1% of patients with MDD
had insomnia symptoms. These patients also had more severe
depressive symptoms than did the patients without insomnia
symptoms (8). Another clinic-based study on patients with
depressive disorder showed that 93% of them reported insomnia
symptoms. Patients with depression and more severe insomnia
(high insomnia) had more severe depressive symptoms than did
those with less severe insomnia (low insomnia) (12).
Cross-sectional studies can obtain extensive information on
exposures and outcomes, require a short time to conduct,
and can acquire snapshot data, including prevalence (13).
Population-based studies can represent the status of disorders
in the general population (14). Hence, population-based cross-
sectional studies can provide insight into the relationships
between various disorders in the general population and may
identify the association between certain disorders at a given
point. Nevertheless, to the best of our knowledge, there is
no information on the impact of insomnia on the clinical
presentation of depression in a cross-sectional population-
based setting.
The gold standard method of diagnosing insomnia and
depression is based on established diagnostic criteria (7,
15). Nevertheless, this strategy is difficult to implement in
epidemiological studies; therefore, a previous study evaluated
insomnia and depressive symptoms, as well as their association,
with a validated questionnaire (10).
Based on the results of previous studies, we hypothesized that
individuals with clinically significant depressive symptoms had
a higher risk of having clinically significant insomnia symptoms
than those without depressive symptoms, and that among
individuals with clinically significant depressive symptoms,
those with clinically significant insomnia symptoms would
have more severe symptoms of depressive symptoms than
those without clinically significant insomnia symptoms (8–10,
12, 16). This study was aimed to investigate the impact of
insomnia symptoms on the prevalence and clinical presentation
of clinically significant depressive symptoms and vice versa using
data from a nationally representative sample.
MATERIALS AND METHODS
Survey
This study used data from the Korean Headache-Sleep Study
(KHSS). The KHSS was a nationwide, cross-sectional survey
of headache and sleep among adults aged 19–69 years in the
Republic of Korea. The survey included items for headache,
sleep, and their covariates, including depressive symptoms.
The design, methods, and process of the KHSS have been
described in detail in previous studies (17). Briefly, the study
used a two-stage clustered random sampling method for all
territories in the Republic of Korea, except Jeju-do. Sixty basic
administrative units (cities and counties) were selected from 15
administrative divisions, and sampling was conducted. Seven
cities were classified as large cities, while the rest were classified
as medium-to-small cities; the counties were classified as rural
areas. A target sample number for each division and basic
administrative unit was determined based on the population
distribution of the Republic of Korea. The estimated sampling
error was 1.8% with a 95% confidence interval (CI). The survey
was performed via door-to-door visits and face-to-face interviews
by trained interviewers using questionnaires. All the interviewers
were employees of Gallup Korea and had previous experience in
conducting social surveys. Data collection was performed from
November 2011 to January 2012. The KHSS was approved by the
institutional review board/ethics committee of HallymUniversity
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Sacred Heart Hospital (IRB No. 2011–I077). Written informed
consent was obtained from all the participants.
Assessment of Clinically Significant
Insomnia Symptoms
In this study, we used the Insomnia Severity Index (ISI), which
is a self-reporting tool to measure a patient’s perception of
the severity of his/her insomnia during the previous 2 weeks,
to diagnose and assess the severity of clinically significant
insomnia symptoms. The ISI comprises the following items: 1a,
difficulties in sleep onset; 1b, difficulties in sleep maintenance;
1c, early awakening in the morning; 2, dissatisfaction with
current sleep pattern; 3, interference of sleep problems with
daily functioning; 4, noticeability of the impairments attributed
to sleep problems; and 5, worries caused by sleep problems.
Each item was rated on a five-point Likert scale of 0–4 (items
1a–c: 0 = no problem, 4 = very severe problem; item 2, 0
= very satisfied, 4 = very dissatisfied; items 3–5, 0 = not at
all, 4 = very much) (18). Higher total scores indicate greater
insomnia severity. A cutoff score of 10 was optimal (86.1%
sensitivity and 87.7% specificity) for detecting insomnia cases in
a previous epidemiological study of insomnia (19). The single
item “non-refreshing sleep in the morning” (0 = not at all, 4
= very much) was also assessed as an additional parameter.
This study refers to clinically significant insomnia symptoms as
insomnia symptoms.
Assessment of Clinically Significant
Depressive Symptoms
Clinically significant depressive symptoms was evaluated by
using the Patient Health Questionnaire-9 (PHQ-9), which is a
self-reported measure of depressive symptoms comprising nine
items matching the DSM-IV criteria of MDD: 1, little interest or
pleasure in doing things; 2, feeling down, depressed, or hopeless;
3, trouble with sleep; 4, feeling tired or having little energy; 5, poor
appetite or overeating; 6, feeling bad about yourself; 7, trouble
concentrating on things; 8, moving or speaking too slowly or too
fast; and 9, suicidal thoughts. Respondents were asked to rate
each of the items on a scale of 0 (not at all) to 3 (nearly every
day) on the basis of how frequently a symptom had bothered
them over the last 2 weeks. The scores from each of the items
were summed to give a total score ranging from 0 to 27 (20).
A cut-off score of ≥10 on the summed-item score has been
recommended as a method of screening for MDD in the Korean
version of PHQ-9 (81.8% sensitivity and 89.9% specificity), with
an excellent value (0.944) of the area under curve (21). This
study refers to clinically significant depressive symptoms as
depressive symptoms.
Statistical Analyses
We evaluated the impact of insomnia symptoms on the
prevalence of depressive symptoms by calculating the age- and
sex-adjusted odds ratio (OR): the ratio of the odds of having
depressive symptoms in participants with insomnia symptoms
to the odds in participants without insomnia symptoms, as
determined, using logistic regression analyses. To investigate the
impact of insomnia symptoms on the clinical presentation of
depressive symptoms, we compared the severity of depressive
symptoms (PHQ-9 score) between participants with depressive
symptoms who had and did not have insomnia symptoms
using multiple linear regression analyses after adjusting for
age and sex. For assessing the impact of depressive symptoms
on the prevalence on insomnia symptoms, we determined
the age- and sex-adjusted OR of having insomnia symptoms
between participants with and without depressive symptoms. We
evaluated the impact of depressive symptoms on the clinical
presentation of insomnia symptoms by comparing the severity
of insomnia (ISI score) between participants with insomnia
symptoms who had and did not have depressive symptoms
using multiple linear regression analyses after adjusting for
age and sex. Since the prevalence and severity of insomnia
and depressive symptoms significantly vary with age (22–24),
we further evaluated the associations between insomnia and
depressive symptoms by dividing the participants into age groups
of 19–35, 36–52, and 53–69 years.
We set the level of significance for the two-tailed tests at 0.05.
Statistical analyses were performed using IBM SPSS forWindows
version 23.0 (IBM Corp., Armonk, NY, USA).
RESULTS
Survey
The interviewers contacted 7,430 individuals, and 3,114 of
them agreed to the survey. Of those who initially agreed, 419
individuals withdrew from the survey. In total, 2,695 participants
completed the survey without any missing data, except education
level (cooperation rate of 36.3%; Figure 1). The distributions of
age, sex, size of residential area, and education level were not
significantly different from those of the general population of the
Republic of Korea (Table 1) (25).
Prevalence of Insomnia and Depressive
Symptoms
Of the 2,695 participants who completed the survey, 290 (10.8%)
had an ISI ≥ 10 and were classified as having insomnia
symptoms. One hundred and sixteen had a PHQ-9 score ≥ 10
and were classified as having depressive symptoms (Table 1).
Impact of Insomnia Symptoms on the
Prevalence of Depressive Symptoms
Among 290 participants with insomnia symptoms, 75 were also
classified as having depressive symptoms. Additionally, 41 of
the 2,405 individuals without insomnia symptoms had PHQ-
9 scores indicating depressive symptoms. The prevalence of
depressive symptomswas significantly higher among participants
with insomnia symptoms than among those without insomnia
symptoms (25.9 vs. 1.7%, P < 0.001; Figure 2). The age- and
sex-adjusted OR for the prevalence of depressive symptoms with
respect to the presence or absence of insomnia symptoms was
21.8 (95% CI= 14.1–33.7).
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FIGURE 1 | Flow chart depicting the participation of individuals in the Korean Headache-Sleep Study.
TABLE 1 | Sociodemographic characteristics of the survey participants, total population in the Republic of Korea, and survey cases identified as having depressive
symptoms and insomnia symptoms.
Survey participants Total population (25) P-value Depressive symptoms† Insomnia symptoms‡
N (%) N (%) N, % (95% CI) N, % (95% CI)
Sex
Male 1,345 (49.9) 17,584,365 (50.6) 0.854* 43, 3.2 (2.3–4.2) 117, 8.7 (7.2–10.2)
Female 1,350 (50.1) 17,198,350 (49.4) 73, 5.4 (4.2–6.6) 173, 12.8 (11.0–14.6)
Age (in years)
19–29 542 (20.1) 7,717,947 (22.2) 0.917* 23, 4.2 (2.5–5.8) 59, 10.9 (8.3–13.5)
30–39 604 (22.4) 8,349,487 (24.0) 32, 5.3 (4.6–7.3) 53, 8.8 (6.5–11.0)
40–49 611 (22.6) 8,613,110 (24.8) 24, 4.0 (2.5–5.5) 66, 10.8 (8.3–13.3)
50–59 529 (19.6) 6,167,505 (17.7) 22, 4.2 (2.5–6.0) 63, 11.9 (9.1–14.7)
60–69 409 (15.2) 3,934,666 (11.3) 15, 3.7 (2.0–5.5) 49, 12.0 (8.8–15.1)
Size of residential area
Large cities 1,248 (46.3) 16,776,771 (48.2) 0.921* 57, 4.6 (3.4–5.7) 136, 10.9 (9.2–12.6)
Medium-to-small cities 1,186 (44.0) 15,164,345 (43.6) 47, 4.0 (2.9–5.1) 125, 10.5 (8.8–12.3)
Rural areas 261 (9.7) 2,841,599 (8.2) 12, 4.6 (2.1–7.3) 29, 11.1 (7.3–14.9)
Education level
Middle school or less 393 (14.6) 6,608,716 (19.0) 0.752* 20, 5.1 (3.0–7.4) 62, 15.8 (12.2–19.4)
High school 1,208 (44.8) 15,234,829 (43.8) 49, 4.1 (3.0–5.2) 116, 9.6 (7.9–11.3)
College or more 1,068 (39.6) 12,939,170 (37.2) 47, 4.4 (3.2–5.7) 109, 10.2 (8.4–12.0)
Not responded 26 (0.1) 3, 11.5 (0.0–24.7)
Total 2,695 (100.0) 34,782,715 (100.0) 116, 4.3 (3.6–5.1) 290, 10.8 (9.6–11.9)
*Comparison of sex, age, size of residential area, and education level distributions between the sample in this study and the total population of the Republic of Korea. N, number; CI,
confidence interval.
†Patient Health Questionnaire-9 score ≥ 10.
‡ Insomnia Severity Index score ≥ 10.
Impact of Insomnia Symptoms on the
Clinical Presentation of Depressive
Symptoms
Among participants with depressive symptoms, the total PHQ-
9 scores were not significantly different between individuals with
and without insomnia symptoms (13.0 [10.0–17.0] vs. 12.0 [11.0–
13.5], P = 0.124). Of the nine PHQ-9 items, the “trouble with
sleep” score was significantly higher in participants with both
depressive and insomnia symptoms than in participants with
depressive symptoms, but without insomnia symptoms. Scores
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FIGURE 2 | Prevalence of depressive symptoms in participants with insomnia symptoms and those without insomnia symptoms.
TABLE 2 | Total and item scores of the PHQ-9 among individuals with depressive symptoms according to the presence of insomnia symptoms.
Individuals with depressive and insomnia
symptoms, N = 75
Individuals with depressive symptoms, but
no insomnia symptoms, N = 41
P-value*
Median (25–75%) Median (25–75%)
1. Little interest or pleasure in doing things 2.0 (1.0–2.0) 2.0 (1.0–2.0) 0.561
2. Feeling down, depressed or hopeless 2.0 (1.0–2.0) 2.0 (1.0–2.0) 0.352
3. Trouble with sleep 2.0 (2.0–3.0) 1.0 (2.0–3.0) <0.001
4. Feeling tired or having little energy 2.0 (2.0–3.0) 2.0 (1.0–2.5) 0.028
5. Poor appetite or overeating 2.0 (1.0–3.0) 2.0 (1.0–3.0) 0.795
6. Feeling bad about yourself 1.0 (0.0–2.0) 2.0 (0.5–2.0) 0.951
7. Trouble concerning on things 1.0 (0.0–2.0) 1.0 (1.0–2.0) 0.512
8. Moving or speaking too slow or too fast 1.0 (0.0–2.0) 0.0 (0.0–1.0) 0.635
9. Suicidal thoughts 1.0 (0.0–2.0) 1.0 (0.0–2.0) 0.565
Total 13.0 (10.0–17.0) 12.0 (11.0–13.5) 0.076
N, number; PHQ-9, Patient Health Questionnaire-9.
*Multiple linear regression analyses adjusting age and sex.
on the other items of the PHQ-9 did not significantly differ
between the two groups (Table 2).
Impact of Depressive Symptoms on the
Prevalence of Insomnia Symptoms
Among 116 participants with depressive symptoms, 75 (64.7%)
were also classified as having insomnia symptoms. In addition,
215 (8.3%) of the 2,579 participants without depressive
symptoms were classified as having insomnia symptoms
(Figure 3). The prevalence of insomnia symptoms among
participants with depressive symptoms was significantly higher
than that among participants without depressive symptoms (P
< 0.001). The age- and sex-adjusted OR for the prevalence of
insomnia symptoms with respect to the presence or absence of
depressive symptoms was 21.5 (95% CI= 13.9–33.2).
Impact of Depressive Symptoms on the
Clinical Presentation of Insomnia
Symptoms
The total ISI scores were significantly higher among participants
with insomnia and depressive symptoms than among
participants with insomnia, but without depressive symptoms
(17.0 [12.0–21.0] vs. 12.0 [11.0–15.0], P < 0.001). Additional
analyses of the seven ISI items demonstrated that scores on
all items, except “early awakening in the morning,” were
significantly higher in the participants with insomnia and
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FIGURE 3 | Prevalence of insomnia symptoms in participants with depressive symptoms and those without depressive symptoms.
TABLE 3 | Total and item scores of the ISI among individuals with insomnia symptoms according to the presence of depressive symptoms.
Individuals with insomnia and depression
symptoms, N = 75
Individuals with insomnia symptoms but
no depressive symptoms, N = 215
P-value*
Median (25–75%) Median (25–75%)
Falling asleep 3.0 (2.0–4.0) 2.0 (1.0–3.0) 0.001
Staying asleep 3.0 (1.0–3.0) 2.0 (1.0–3.0) <0.001
Early awakening 2.0 (1.0–3.0) 2.0 (1.0–3.0) 0.089
Non-refreshing sleep in the morning 3.0 (3.0–4.0) 2.0 (1.0–3.0) <0.001
Satisfaction with current sleep pattern 4.0 (4.0–5.0) 4.0 (3.0–4.0) <0.001
Interference with daily functioning 3.0 (2.0–4.0) 3.0 (2.0–4.0) 0.004
Impaired quality of life 3.0 (2.0–4.0) 3.0 (2.0–3.0) 0.001
Worry about current sleep problems 3.0 (2.0–4.0) 3.0 (2.0–3.0) <0.001
Total 17.0 (12.0–21.0) 12.0 (11.0–15.0) <0.001
N, number; ISI, Insomnia Severity Index.
*Multiple linear regression analyses after adjusting for age and sex.
depressive symptoms than in those with insomnia but without
depressive symptoms. Moreover, the score for the additional item
“non-refreshing sleep in the morning” was significantly higher
among participants with insomnia and depressive symptoms
than among those with insomnia symptoms alone (Table 3).
Impact of Insomnia Symptoms on the
Prevalence and Clinical Presentation of
Depressive Symptoms According to Age
The prevalence of depressive symptoms among participants
with insomnia symptoms was significantly higher than
among participants without insomnia symptoms in all
age groups. Among the participants with depressive
symptoms, the total PHQ-9 scores were not significantly
different between participants with and without insomnia
symptoms in all age groups (Supplementary Table 1A and
Supplementary Table 2A).
Impact of Depressive Symptoms on the
Prevalence and Clinical Presentation of
Insomnia Symptoms at Different Age
Groups
The prevalence of insomnia symptoms among participants
with depressive symptoms was significantly higher than
among participants without insomnia symptoms in all age
groups. Among the participants with insomnia symptoms, the
total ISI scores were significantly higher among participants
with depressive symptoms than those without depressive
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symptoms in all age groups (Supplementary Table 1B and
Supplementary Table 2B).
DISCUSSION
The key findings of this study were as follows: 1. The prevalence
of insomnia and depressive symptoms in the adult population
of the Republic of Korea was 10.8 and 4.3%, respectively. 2. The
prevalence of depressive symptoms was higher in the participants
with insomnia symptoms than in the participants without
insomnia symptoms; nevertheless, the severity of depressive
symptoms did not significantly differ between participants with
depressive and insomnia symptoms and those with depressive
symptoms, but without insomnia symptoms. 3. The prevalence
of insomnia symptoms was higher in participants with depressive
symptoms than in participants without depressive symptoms;
moreover, the severity of insomnia symptoms was higher in
the participants with insomnia and depressive symptoms than
in the participants with insomnia symptoms, but without
depressive symptoms.
Based on the findings in this study, we accepted the
hypothesis that participants with insomnia symptoms had an
increased risk of depressive symptoms. Nevertheless, we had
to reject the hypothesis that the severity of the depressive
symptoms was higher in the participants with depressive and
insomnia symptoms than in the participants with depressive
symptoms alone.
Although the close association between insomnia and
depression has been consistently reported in cross-sectional and
longitudinal studies, information on the impact of insomnia
symptoms on the prevalence and clinical presentation of
depressive symptoms is limited. This study is the first report
to compare the impact of insomnia symptoms on the clinical
presentation of depressive symptoms with the impact of
depressive symptoms on the clinical presentation of insomnia
symptoms in a population setting.
Two previous clinical studies have assessed the severity of
depressive symptoms according to the presence of insomnia.
The STARD∗D study, which enrolled patients with depression
in clinics, reported that the depressive symptoms in patients
with insomnia symptoms were more severe than that in those
without insomnia symptoms (8). The CRESCEND study of
patients with depression revealed that patients with depression
and high insomnia had more severe depressive symptoms than
did patients with depression and low insomnia (12). These
findings contradicted the present finding that the severity of
depressive symptoms in participants with depression did not
change according to the severity of insomnia symptoms. One
possible explanation for the discrepancy between the present
and previous findings may be attributed to the study settings.
The two previous studies were conducted in clinical settings,
while this was a population-based study. Different study setting
between clinic-based and population-based studies may result in
different outcomes.
One explanation for the impact of insomnia symptoms
on depressive symptoms and vice versa may involve possible
differences in a shared mechanism underlying each condition.
Reductions in total sleep time, sleep efficiency, and slow wave
sleep time have been observed in individuals with depression
as well as in individuals with insomnia (26, 27). However,
significant changes in rapid eye movement (REM) sleep,
including a decrease in REM latency, an increase in the
proportion of REM sleep, and elevated REM density, were
observed in individuals with depression, whereas there was no
change in these parameters in those with primary insomnia
(28–30). These findings suggest that there is a difference between
depression and insomnia with respect to the physiological
mechanisms of REM sleep. Dysregulation of REM sleep and
depression were related to dysfunction of the monoaminergic
system (31). The depletion of monoamines by the administration
of reserpine induced depression and acceleration of REM sleep
(32). An increase in extracellular 5-hydroxytryptamine (5-HT)
improved depression and inhibited REM sleep (33). Studies
on serotonergic dysfunction in primary insomnia revealed
conflicting results. 5-hydroxytryptamine neurons promoted
wakefulness, and insomnia caused by 5-HT depletion was due
to hypothermia rather than a sleep-inducing effect (34, 35).
Selective serotonin reuptake inhibitors were effective in patients
with insomnia who did not have depression (36). Differences
in the hypothalamus-pituitary-adrenal (HPA) system have also
been reported between patients with depression and those with
insomnia: specifically, elevated activity of the HPA system in
patients with insomnia (37–39). Urinary free cortisol (UFC)
has been used as an indicator of the activity of HPA system
(40). Patients with insomnia showed elevated UFC levels,
and their level of 24-h UFC was positively correlated with
wake time (37). Among individuals with depression, elevated
HPA system activity was also observed (41–43). Nevertheless,
findings regarding UFC levels have been inconsistent. Some
studies reported no significant differences between patients with
depression and those without, while others found increased UFC
levels in patients with depression (44, 45). These findings suggest
that depression and primary insomnia share a pathophysiological
mechanism, but that some aspects are distinct from
one another.
Among the PHQ-9 items, scores on the items for “trouble
with sleep” and “feeling tired or have little energy” were higher
among participants with depression and insomnia symptoms
than among participants with depressive symptoms alone.
This may be due to the characteristics of the items. The
PHQ-9 was constructed based on the nine criteria for the
diagnosis of MDD according to the DSM-IV, which included
sleep problems as one of the criteria (20). Consequently,
participants with depressive and insomnia symptoms more
frequently responded positively to the item “trouble with
sleep” than did those with depression but without insomnia
symptoms. Hence, the higher score for the item “feeling
tired or have little energy” among participants with depressive
and insomnia symptoms may be attributed to the nature
of the item. Feeling tired and having little energy is key
symptoms for both insomnia and depression (46, 47). Therefore,
individuals with depression on feeling tired or having little
energy had more depressive symptoms; they might have
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more severe depressive symptoms (20). Nevertheless, the
remaining seven items, which were not directly related to
sleep, did not significantly differ based on the status of
insomnia symptoms.
In a prior study, the ISI was evaluated for its validity
and reliability for classifying insomnia through mail in 959
community-based individuals. Based on the responses and
analyses using receiver operating curves, a cut-off value of 10
showed optimal results (19). The ISI showed a good correlation
with sleep diaries and polysomnographic results among 183
individuals with insomnia. Furthermore, the ISI showed a good
sensitivity to detect clinical improvements after treatment (19).
The items of the ISI comprise insomnia symptoms and their
consequences (18). In these studies, the insomnia prevalence
based on insomnia symptoms and daytime consequences mostly
ranged from 9 to 15%, which was similar to that in this study (4).
The prevalence of depressive symptoms in this study was
4.3%, which was comparable to those observed in previous
studies. Studies using the Composite International Diagnostic
Interview, Diagnostic Interview Schedule, and DSM-III to
classify depression showed that the prevalence of depression in
the Republic of Korea ranged from 1.3 to 4.0% (23, 48, 49).
Among studies using the PHQ-9, the prevalence of depressive
symptoms ranged between 4.2 and 6.4%.
This study showed the point prevalence of insomnia
symptoms as 10.8%. Although a variety of diagnostic criteria
or instruments were used, previous reports on the prevalence
of insomnia symptoms have ranged widely from 5.0 to 22.8%
(50, 51). The prevalence of insomnia symptoms in this study is
within this previously reported range. Furthermore, a Canadian
population-based study using the ISI reported the prevalence of
insomnia observed as 7.4% (52), which was similar to our study.
The similarity in the prevalence of depressive and insomnia
symptoms between this study and previous studies suggests
the reliability of the assessment of depression and insomnia
symptoms in the present study.
The findings of this study may be helpful in the management
of insomnia and depression. If an individual is diagnosed with
insomnia or depression, an assessment of the other disease is
urgently needed since the risk of comorbidity is remarkably
high. In addition to providing insight into the relationship
between the two disorders, the results of our study also provide
additional prospects in the understanding of the nature of
insomnia and depression.
This study found that 64.7% of participants with depressive
symptoms had insomnia symptoms. It has been previously
reported that approximately 50–70% of individuals with
depression experienced insomnia (53, 54). Thus, depression
could be classified according to the presence of insomnia
(depression with insomnia vs. depression without insomnia)
considering the close relationship of the two disorders. Similarly,
insomnia could be classified as insomnia with depression and
insomnia without depression (depressive insomnia vs. non-
depressive insomnia). Our findings would also be useful in
medical policy making. The severity of the disease is an
important factor in determining the priority of medical care
(55). If an individual has both insomnia and depression, the
symptoms of insomnia experienced would be more severe than
those experienced in insomnia without depression; therefore,
individuals with both insomnia and depression should be
considered as a priority for treatment of insomnia. The severity of
depression in individuals with insomnia is less likely to be more
severe than their counterparts without insomnia. Nevertheless,
both depression and insomnia are serious disorders, and the
proper treatment of accompanying insomnia is urgently needed
in individuals with depression.
This was a cross-sectional study and could not provide
definitive information on the casual association between
depressive and insomnia symptoms but could provide an
insight to infer causations (56). The present study observed
that the participants with insomnia had an increased prevalence
of depression and those with depression had an increased
prevalence of insomnia. These findings suggest a possibility of
an increased risk of developing depression in individuals with
insomnia and vice versa. As expected, a significant bidirectional
association between insomnia and depressive symptoms has
been reported in longitudinal studies (9–11, 57). For the
impact of depressive symptoms on the clinical presentation of
insomnia symptoms, we can hypothesize that individuals with
insomnia symptoms combined with depressive symptoms would
develop more severe insomnia symptoms than counterparts
without depressive symptoms in follow-up. In contrast,
individuals with depressive symptoms combined with insomnia
symptoms can be hypothesized that their depressive symptoms
may not significantly differ from those without insomnia
symptoms in follow-up. Nevertheless, such associations
have not been reported and further longitudinal studies will
confirm the complex relationship between insomnia and
depressive symptoms.
This study has some limitations. First, we did not assess
the use of medications for insomnia or depression. Insomnia
and depression are common disorders in the general population
and a significant proportion of individuals use medications for
depression and insomnia (58, 59). Medications for depression
and insomnia may affect the prevalence and symptom severity
of both disorders (60, 61). Second, this study used data from
the KHSS, which were collected in 2011 and 2012. Therefore,
this study provides information on the status and association
between depression and insomnia as of 9 years ago. Nevertheless,
as the prevalence of depression and insomnia has remained stable
over the past 9 years in the Republic of Korea (49, 62), the
findings of this study may still be valid. Lastly, we evaluated
insomnia symptoms based on the ISI rather than using objective
measures such as actigraphy or polysomnography. Insomnia
symptoms could occur due to various causes including restless
legs syndrome, obstructive sleep apnea, sleep-related movement
disorder, and so forth (63). Therefore, the insomnia symptoms
reported by the respondents in this study were attributable to
various conditions.
Our study also has several strengths. First, this study
used a population-based sample with a large sample
size that used two-stage clustered sampling methods
proportional to the population distribution of the Republic
of Korea. In addition, the estimated sampling error was low.
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Consequently, we could accurately investigate the impact
of insomnia on the prevalence and clinical characteristics
of depression in a population-based setting. Furthermore,
we investigated depressive and insomnia symptoms using
validated questionnaires, which have shown high sensitivity
and specificity. Given the similarities in the prevalence of
depressive and insomnia symptoms with previous studies and
use of valid questionnaires, we are assured that we accurately
evaluated depressive and insomnia symptoms in our study.
Lastly, this study explored the impact of insomnia symptoms
on depressive symptoms along with the impact of depressive
symptoms on insomnia symptoms, which has rarely been
studied previously.
CONCLUSIONS
In conclusion, both depressive and insomnia symptoms
were prevalent conditions in a general population-based
sample from the Republic of Korea. Participants with
depressive symptoms showed a higher prevalence of
insomnia symptoms than participants without depressive
symptoms. However, the severity of depressive symptoms
was not significantly affected by the presence of insomnia
symptoms. The prevalence of depressive symptoms was
higher among participants with insomnia symptoms than
among those without insomnia symptoms. Participants
with both insomnia and depressive symptoms showed more
severe insomnia symptoms than participants with insomnia
symptoms alone.
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